Active surveillance for intermediate-risk prostate cancer

Introduction. Prostate cancer (PCa) is one of the most common malignant diseases in men in the world. Radical prostatectomy remains the «gold standard» for treating this pathology. Good long-term oncological results Active follow-up of low-risk patients, as well as modification of the Gleason scale, suggested the possibility of using AS in carefully selected patients with intermediate-risk PCa. The introduction of molecular genetic markers into practice will allow a personalized choice of a treatment method. Purpose. Conduct a systematic review of the literature on the analysis of active surveillance in patients with PCa of an intermediate risk group, existing molecular genetic markers for additional risk stratification. Materials and methods. A systematic review of publications on active surveillance in prostate cancer, published in the PubMed, Cochrane, e-Library databases, was performed. Databases were searched using the following keywords: active surveillance, prostate cancer, intermediate risk, molecular genetic markers. Results. This review selected 39 articles, of which 24 are devoted to Active Surveillance, 15 molecular genetic markers of PCa aggressiveness. In the analysis of active surveillance, parameters such as the percentage of patients without active (radical) treatment, overall survival, tumor-specific survival, and metastasis-free survival were evaluated. Conclusions. Currently, AS in prostate cancer can be used for carefully selected group of patients at an intermediate risk group, the introduction of modern molecular genetic markers will allow more accurate determination of the amount of treatment without worsening long-term oncological results.